Trough ganciclovir concentration as predictor of leukopenia in lung transplant recipients receiving valganciclovir prophylaxis

被引:5
作者
Katada, Yoshiki [1 ,2 ]
Nakagawa, Shunsaku [1 ]
Nagao, Miki [2 ,3 ]
Umemura, Keisuke [1 ]
Itohara, Kotaro [1 ]
Nishikawa, Asami [1 ,2 ]
Hashi, Sachiyo [1 ]
Katsube, Yurie [1 ]
Hira, Daiki [1 ]
Ohsumi, Akihiro [4 ]
Nakajima, Daisuke [4 ]
Date, Hiroshi [4 ]
Terada, Tomohiro [1 ]
机构
[1] Kyoto Univ Hosp, Dept Clin Pharmacol & Therapeut, 54 Shogoin Kawahara Cho,Sakyo Ku, Kyoto 6068507, Japan
[2] Kyoto Univ Hosp, Dept Infect Control & Prevent, Sakyo Ku, Kyoto, Japan
[3] Kyoto Univ, Grad Sch Med, Dept Clin Lab Med, Sakyo Ku, Kyoto, Japan
[4] Kyoto Univ, Grad Sch Med, Dept Thorac Surg, Sakyo Ku, Kyoto, Japan
关键词
Cytomegalovirus; ganciclovir; lung transplantation; prophylaxis; therapeutic drug monitoring; valganciclovir; CYTOMEGALOVIRUS-INFECTION; DOSE VALGANCICLOVIR; PREEMPTIVE THERAPY; PHARMACOKINETICS; MANAGEMENT; OUTCOMES;
D O I
10.1111/tid.14141
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Valganciclovir is the first-line agent for Cytomegalovirus prophylaxis after lung transplantation. However, its use is associated with a relatively high risk of hematological toxicity. This study aimed to investigate the relationship between trough ganciclovir concentration and hematologic toxicity in lung transplantation patients receiving valganciclovir prophylaxis, and identify factors that affect ganciclovir pharmacokinetics in this population. Methods: This prospective observational study included 24 lung transplant patients receiving valganciclovir prophylaxis. The cutoff value of trough ganciclovir concentration was estimated using receiver operating characteristic analysis in leukopenia grade 3 and higher. Population pharmacokinetic analysis was performed using a nonlinear mixed-effects modeling program. Results: The trough ganciclovir concentration was significantly higher in the group with leukopenia grades 3 or higher than in the group with grades less than or equal to 2 (1605.7 +/- 860.1 ng/mL [n = 3] vs. 380.5 +/- 175.8 ng/mL (n = 21), p < .001). The cutoff value of trough ganciclovir concentration for predicting greater than or equal to grade 3 leukopenia was estimated as 872.0 ng/mL. Creatinine clearance and lung re-transplantation were found to have a significant impact on the total body clearance of valganciclovir. Ganciclovir clearance was decreased in patients with reduced creatine clearance or re-transplantation. Conclusion: These results suggest that higher ganciclovir trough concentrations are associated with an increased risk of leukopenia grade 3 or higher, and that creatinine clearance and lung re-transplantation affected the pharmacokinetics of ganciclovir.
引用
收藏
页数:9
相关论文
共 33 条
[1]   Prediction-Corrected Visual Predictive Checks for Diagnosing Nonlinear Mixed-Effects Models [J].
Bergstrand, Martin ;
Hooker, Andrew C. ;
Wallin, Johan E. ;
Karlsson, Mats O. .
AAPS JOURNAL, 2011, 13 (02) :143-151
[2]   Comparison of standard versus low-dose valganciclovir regimens for cytomegalovirus prophylaxis in high-risk liver transplant recipients [J].
Bixby, Alexandra L. ;
Fitzgerald, Linda ;
Park, Jeong M. ;
Kaul, Daniel ;
Tischer, Sarah .
TRANSPLANT INFECTIOUS DISEASE, 2021, 23 (05)
[3]   Pharmacokinetics of low and maintenance dose valganciclovir in kidney transplant recipients [J].
Chamberlain, C. E. ;
Penzak, S. R. ;
Alfaro, R. M. ;
Wesley, R. ;
Daniels, C. E. ;
Hale, D. ;
Kirk, A. D. ;
Mannon, R. B. .
AMERICAN JOURNAL OF TRANSPLANTATION, 2008, 8 (06) :1297-1302
[4]   Outcomes following lung re-transplantation in patients with cystic fibrosis [J].
Chan, Ernest G. ;
Hyzny, Eric J. ;
Ryan, John P. ;
Morrell, Matthew R. ;
Pilewski, Joseph ;
Sanchez, Pablo G. .
JOURNAL OF CYSTIC FIBROSIS, 2022, 21 (03) :482-488
[5]  
DAVIS CL, 1990, NEW ENGL J MED, V322, P933
[6]  
Disease Kidney. Improving global outcomes (KDIGO) acute kidney injury work group, 2012, Kidney Int Suppl, V2, P2, DOI DOI 10.1038/KISUP.2012.1
[7]   Subtherapeutic ganciclovir (GCV) levels and GCV-resistant cytomegalovirus in lung transplant recipients [J].
Gagermeier, J. P. ;
Rusinak, J. D. ;
Lurain, N. S. ;
Alex, C. G. ;
Dilling, D. F. ;
Wigfield, C. H. ;
Love, R. B. .
TRANSPLANT INFECTIOUS DISEASE, 2014, 16 (06) :941-950
[8]   Drug-resistant cytomegalovirus infection after lung transplantation: Incidence, characteristics, and clinical outcomes [J].
Heliovaara, Elina ;
Husain, Shahid ;
Martinu, Tereza ;
Singer, Lianne G. ;
Cypel, Marcelo ;
Humar, Atul ;
Keshavjee, Shaf ;
Tikkanen, Jussi .
JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2019, 38 (12) :1268-1274
[9]   A Pharmacokinetic Standard for Babies and Adults [J].
Holford, Nick ;
Heo, Young-A ;
Anderson, Brian .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2013, 102 (09) :2941-2952
[10]   Pharmacokinetics of Ganciclovir during Continuous Venovenous Hemodiafiltration in Critically Ill Patients [J].
Horvatits, Thomas ;
Kitzberger, Reinhard ;
Drolz, Andreas ;
Zauner, Christian ;
Jaeger, Walter ;
Boehmdorfer, Michaela ;
Kraff, Stefanie ;
Fritsch, Achim ;
Thalhammer, Florian ;
Fuhrmann, Valentin ;
Schenk, Peter .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2014, 58 (01) :94-101